Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. on July 31, 2017. The report details the completion of a single-center clinical study for the investigational drug AKB-9778 in collaboration with Dr. Peter Campochiaro of the Wilmer Eye Institute at Johns Hopkins Medical Center.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements.
Material Changes and Clinical Results
The Company reported the completion of a study involving 16 patients with retinal vein occlusion (RVO) and persistent macular edema despite anti-VEGF monotherapy. Key findings include:
- Study Design: Open-label, non-controlled study with no placebo or active control arm.
- Treatment: 15 mg AKB-9778 twice daily for three months, with concomitant PRN anti-VEGF therapy.
- Visual Acuity: Improved from baseline by a mean of 8.7 letters (p=0.001).
- Macular Edema: Significant reduction in central subfield thickness on sd-OCT (mean reduction 140 µm; p=0.009).
- Anti-VEGF Usage: 12 of 16 patients received at least one intravitreal anti-VEGF dose during the active treatment period, totaling 14 injections (0.88 injections/patient).
- Safety: AKB-9778 was safe and well-tolerated with no serious or severe adverse events reported.
Guidance, Outlook, and Risks
Management believes the results suggest that activation of Tie2 by AKB-9778 may be beneficial for patients with chronic retinal vein occlusion. However, the Company explicitly states that these results are considered exploratory due to the study's open-label, non-controlled nature. No specific financial guidance or future operational outlook was provided in this filing.
Investor Verification Checklist
- Verify the exploratory nature of the data due to the lack of a control arm.
- Confirm the patient population characteristics (average RVO duration of 4.7 years).
- Review the safety profile details regarding the absence of serious adverse events.
- Check for subsequent filings regarding the next phase of clinical development for AKB-9778.